Trial Profile

A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa).

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jan 2026 Planned number of patients changed from 204 to 250, according to Telix Pharmaceuticals media release.
17 Jan 2026 According to Telix Pharmaceuticals media release, first patient in the United States (U.S.) has been dosed with Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection).
14 Oct 2025 According to Telix media release, company has commenced the study in Melbourne, Australia.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com